# A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab

> **NCT06513221** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 100 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Chemotherapy, Bevacizumab, Adebrelimab

## Key facts

- **NCT ID:** NCT06513221
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-25
- **Primary completion:** 2026-04-01
- **Final completion:** 2027-04-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06513221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06513221, "A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06513221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*